|
Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") (Details Textual) (USD $)
|
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
|
Aug. 31, 2012
|
Aug. 31, 2011
|
Aug. 31, 2012
|
Aug. 31, 2011
|
Nov. 30, 2011
|
|
| Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") (Textual) [Abstract] | |||||
| Value of treasury stock | $ 1,955,261 | $ 1,955,261 | $ 484,535 | ||
|
Saneron [Member]
|
|||||
| Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") (Textual) [Abstract] | |||||
| Ownership interest | 34.00% | 34.00% | 34.00% | ||
| Goodwill | 684,000 | 684,000 | 684,000 | ||
| Equity losses related to stock and warrants | 38,000 | 36,000 | 116,000 | 92,000 | |
| Value of treasury stock | $ 485,000 | $ 485,000 | $ 485,000 | ||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the amount of gain (loss) arising from the disposal of an equity method investment. No definition available.
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|